DHB Supplementation to Overcome Lipolysis Resistance in EODF

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Every-other-day intermittent fasting (EODF) treatments face challenges with lipolysis resistance in white adipose tissues, compromising weight loss efficacy, particularly in visceral lipid stores.

Innovation Solution

Administering Dihydroberberine (DHB) synergistically with EODF to enhance fat mobilization and weight loss benefits, including reducing body fat, improving insulin and leptin resistance, and regulating ADRB3 abundance in white adipose tissues.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If every-other-day intermittent fasting (EODF) is implemented for weight loss, then insulin levels are lowered and glucose tolerance is improved, but lipolysis is downregulated in white adipose tissues leading to visceral fat preservation

Engineering Contradiction:

Improvevisceral lipid storeVSAvoidweight loss efficacy

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent introduces DHB as an intermediary substance that mediates between EODF and lipolysis regulation. DHB activates ADRB3 receptors directly, bypassing the EODF-induced downregulation pathway, thereby restoring lipolysis activity in white adipose tissue without interfering with the metabolic benefits of intermittent fasting

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biochemical parameter of ADRB3 receptor abundance and activity in white adipose tissue through DHB administration. By supplementing DHB, the system compensates for the reduced receptor abundance caused by EODF, effectively reversing the lipolysis resistance phenotype while maintaining the fasting-induced metabolic improvements

Inventive Principle:

Principle #35Parameter changes

2Weight of moving object

If EODF is used to promote weight loss, then overall body weight decreases, but lipolysis resistance develops in white adipose tissues compromising fat mobilization

Engineering Contradiction:

Improvebody weightVSAvoidfat mobilization

Core Design Contradiction:

Weight of moving objectVSReliability

Solution Approach 1:

DHB serves as a mediating compound that specifically targets the lipolysis pathway in white adipose tissue. It compensates for the EODF-induced reduction in ADRB3 receptor activity, ensuring reliable fat mobilization continues despite the weight loss and metabolic adaptations that occur during intermittent fasting

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies preliminary anti-action by administering DHB to counteract the developing lipolysis resistance before it fully compromises weight loss efficacy. The DHB supplementation prevents the detrimental effects of ADRB3 downregulation, maintaining fat mobilization capacity throughout the EODF regimen

Inventive Principle:

Principle #9Preliminary anti-action

Data Source

PatentUS20250360113A1Administration of DHB to increase benefit of losing weight of intermittent fasting

Publication Date: 2025.11.27 NANJING NUTRABUILDING BIO TECH CO LTD

AI summary

The present invention provides methods for increasing a benefit of losing weight of a mammal treated with every-other-day fasting (EODF), comprising administrating to the mammal an effective amount of Dihydroberberine, an analog or derivative thereof, or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof.